Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEO-LM01
- Development stage
- Preclinical
- Lead developer
- GeoVax Labs
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GEO-LM01 is a vaccine candidate developed by GeoVax Labs for the prevention of Lassa Fever, a viral hemorrhagic fever caused by the Lassa virus (LASV). The vaccine utilizes GeoVax's proprietary Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform, which is engineered to express Lassa virus antigens that spontaneously assemble into non-infectious VLPs within the host. This approach is designed to elicit both robust antibody (humoral) and T-cell (cellular) immune responses. Preclinical studies in mouse models have demonstrated 100% protection against lethal Lassa virus challenge. The program has received significant support from the U.S. Department of Defense (DoD) to fund advanced preclinical development, including nonhuman primate testing and cGMP manufacturing process development, in preparation for Phase 1 human clinical trials. Development is conducted in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and The Scripps Research Institute.
- Other names
- GeoVax Lassa fever vaccineGV-MVA-VLP Lassa vaccine
02
Targets
NP (Taï Forest ebolavirus nucleoprotein)GPC (Lassa virus glycoprotein complex)
Beyond the preview
Go deeper on GEO-LM01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEO-LM01.